Obesity biotech Corxel is set to go public in the US via a SPAC, following a disclosed financing structure and the company’s push to advance oral GLP-1 obesity candidates toward Phase 3. The move targets a competitive market where oral metabolic drugs are increasingly contested by both established and newer developers. Corxel’s strategy is to leverage small-molecule differentiation tied to tolerability expectations and operationalize clinical development with the liquidity from a public listing. The company expects the Phase 3 start timing around the anticipated SPAC closing window. For investors and competitors, the transaction is a reminder that obesity remains one of the most actively financed therapeutic categories, with product development and market access aligned to public-market catalysts.